System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof CF Paul is an expert in Dermatology at Centre Hospitalier Universitaire de Toulouse (France). As of October 2026, ScienceLeadR ranks CF Paul in the top 1% of experts worldwide for Psoriasis, Syphilis and Sexually Transmitted Diseases. CF Paul has authored 941 publications, the most recent in 2026, and is an investigator in 25 clinical trials, 1 of them ongoing. SLR score: 2,787 (community average: 125). How the SLR is computed.

LeadR Profile

Prof CF Paul Centre Hospitalier Universitaire de Toulouse France
2 787 ScienceLeadR Reputation 2787

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Immunology - Infectiology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2003 - 2026
Source: PubMed

Hôpital Larrey

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 941

Citations

Citations: 40 801 1st author: 113 Last author: 217 Unique author: 34

Main journals

J Eur Acad Dermatol Venereol 129
Ann Dermatol Venereol 108
Br J Dermatol 68
J Am Acad Dermatol 37
N Z Med J 34

Best Journals

N Engl J Med 8
Science 5
Lancet 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Thirty-five years of JEADV: A conversation with past and present Editors-in-Chief.
PMID 42788403 — sexually transmitted diseases		J Eur Acad Dermatol Venereol20260
Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
PMID 42789172 — safety, alopecia areata, therapeutics, alopecia		Am J Clin Dermatol20260
Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial.
PMID 42562758 — tyk2 kinase, arthritis, psoriatic, safety, c-reactive protein, arthritis, rheumatic diseases, protein-tyrosine kinases, tyrosine		Ann Rheum Dis20261
Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials.
PMID 42563042 — safety, skin diseases, covid-19, therapeutics, psoriasis		Am J Clin Dermatol20261
The spectrum of eosinophilic cellulitis (Wells' syndrome): new insights based on 114 cases.
PMID 42551694 — hypersensitivity, adrenal cortex hormones, cellulitis, eosinophils, therapeutics		J Allergy Clin Immunol Pract20260

Clinical Studies 25

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 20
Phase 2 3
N/A 2

By status:

Completed 24
Recruiting 1

By type:

Interventional 24
Observational 1

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 2
multicentric5to9 0
multicentricup10 18

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A study to learn how safe bimekizumab is and how well it works in adults with palmoplantar pustulosis
2024-520337-80-00 — safety		Phase 3Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS